pGM169/GL67A: Phase IIb data

Data from 116 CF patients ages >=12 in the per protocol (PP) population of a double-blind, U.K. Phase IIb trial showed that once-monthly 5 mL inhaled pGM169/GL67A met the primary endpoint of improving...